{"pub": "morningstar", "url": "https://morningstar.com/news/dow-jones/2019091210720/springworks-therapeutics-ipo-prices-at-high-end-of-range", "downloaded_at": "2019-09-12 23:34:52.687302+00:00", "title": "SpringWorks Therapeutics IPO Prices at High End of Range", "language": "en", "text": "By Josh Beckerman\n\nBiopharmaceutical company SpringWorks Therapeutics Inc. (SWTX) said its initial public offering of 9 million shares priced at $18 each.\n\nOn Sept. 3, SpringWorks said it expected to offer 7.35 million shares at $16 to $18 each. The expected size was increased to 9 million shares earlier Thursday.\n\nPfizer Inc. (PFE), which licensed nirogacestat to SpringWorks in 2017, will have a post-IPO stake of about 10.9%, according to a filing. Bain Capital and OrbiMed Advisors will each own about 17%.\n\nWrite to Josh Beckerman at josh.beckerman@wsj.com\n\n(END) Dow Jones Newswires\n\nSeptember 12, 2019 18:52 ET (22:52 GMT)\n\nCopyright (c) 2019 Dow Jones & Company, Inc.", "description": "", "authors": [], "top_image": "https://morningstar.com/assets/img/30241a1.png", "published_at": "2019-09-12"}